Pomalidomide (POM), bortezomib (BORT), and dexamethasone (DEX) after 1 prior line of therapy in relapsed or refractory multiple myeloma (RRMM): a safety subanalysis of the phase 3 OPTIMISMM trial

Weisel K., Dimopoulos M., Oriol A., BEKSAÇ M., Schjesvold F., LİBERATİ A., ...More

ONCOLOGY RESEARCH AND TREATMENT, United States Of America, 8 - 09 December 2022, (Full Text)

• Publication Type: Conference Paper / Full Text
• Country: United States Of America
• Ankara University Affiliated: Yes